Alliance for Multispecialty Research, LLC

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Obesity6 trials
• Type 2 diabetes4 trials
• Chronic kidney disease2 trials
• ALS (motor neurone disease)1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Gout1 trial
• Heart failure1 trial
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• Melanoma1 trial
• Migraine1 trial
• and 2 more

Phase

• Phase 36 trials
• Phase 23 trials
• Phase 12 trials

Status

• Completed5 trials
• Active, not recruiting2 trials
• Recruiting2 trials
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company4 trials
• Hoffmann-La Roche2 trials
• Amylyx Pharmaceuticals Inc.1 trial
• Carmot Therapeutics, Inc.1 trial
• Incyte Corporation1 trial
• and 2 more

Running trials

• Recruiting

  AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

  NCT06665165· Phase 1· Amylyx Pharmaceuticals Inc.· Source

  Contact: Patricia Pryor

• Recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

  NCT06641466· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

  NCT06859268· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• ALS (motor neurone disease)1 recruiting
• Migraine1 recruiting

Closed trials

• Recruiting

  A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

  NCT07112872· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

  NCT07081958· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

  NCT06525935· Phase 2· Carmot Therapeutics, Inc.· Source

• Terminated

  Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

  NCT05909995· Phase 1· Incyte Corporation· Source

• Completed

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Completed

  Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

  NCT05586971· Phase 3· LG Chem· Source